i.amankwah
TL2 Moderator · Ibadan
Contributes reviews on supplier material. Based in Ibadan.
Joined 5 March 2025 · last posted 19h
70Posts here
3Topics
0Solutions
1.5kLikes received
1.5kLikes given
26Badges
257Days visited
4.7kPosts read
Recent activity
Full stream-
AOD-9604 and the fragment hypothesis, revisited — does this still hold? Replied, post #12 · Compounds › Other compounds · 27 Jul 2026 · 11 likes Compounds this community declines to help with, and why: there are specifics in the guidelines and they are not arbitrary. They exist because of failure modes that have…
-
Reading order for a first week here, and what to skip until later — what changed since Replied, post #89 · Start Here › Welcome · 27 Jul 2026 · 6 likes The FAQ link in the sidebar is maintained and worth ten hours of forum browsing. It is not comprehensive but it is well indexed for the questions that come up most.
-
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #74 · Compounds › Retatrutide · 19 Jul 2026 · 16 likes post #73 answers the question as asked. The question underneath it is different. Mass and identity: a report on retatrutide should state the mass detected by LC-MS, not…
-
Prior authorisation: what the criteria usually require — a second dataset Replied, post #18 · Access › Insurance & coverage · 11 Jul 2026 · 16 likes post #17 is right about the mechanism and I think understates the practical bit. Denial letters: the stated reason tells you exactly what to submit next. A denial is…
-
Type 2 diabetes and the largest part of the evidence base — does this still hold? Replied, post #19 · Clinical › Comorbidities · 7 Jul 2026 · 32 likes post #18 answers the question as asked. The question underneath it is different. For anyone arriving from a search: the marked solution above is the direct answer, and…
-
Restarting after a long gap: what the labelling implies Replied, post #11 · Practice › Dosing & titration · 4 Jul 2026 · 3 likes Coming back to post #9, because the follow-up matters more than the original answer. Reaching a dose and staying there for a year: the question of whether a stable dose…
-
Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Replied, post #39 · Evidence › Journal club · 11 Jun 2026 · 2 likes Coming back to post #37, because the follow-up matters more than the original answer. SOUL (N Engl J Med 2025): Oral semaglutide cardiovascular outcomes. Extends the…
-
[2026 update] A vial that will not fully dissolve: what to check and in what order Replied, post #97 · Practice › Reconstitution · 8 Jun 2026 · 0 likes Worth separating two things that post #93 runs together. A vial that will not fully dissolve: check in order: is the diluent genuinely room temperature (some…
-
Second pass at: Absence of evidence and evidence of absence Replied, post #9 · Research Methods › Statistics · 25 May 2026 · 2 likes P-values and significance: p
-
Second pass at: Leak-back after withdrawal and whether you lost a meaningful dose Replied, post #14 · Practice › Administration · 15 May 2026 · 26 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
-
A checklist for reading a certificate in under two minutes Replied, post #11 · Analytics › COA interpretation · 26 Apr 2026 · 10 likes Counter-ion form is crucial: peptides are isolated as salts, most often trifluoroacetate from reversed-phase purification or acetate after salt exchange. The…
-
About the UK & Ireland category Replied, post #4 · Regional › UK & Ireland · 9 Apr 2026 · 0 likes Suggestion for the wiki post above: it would be worth linking the two or three most-referenced topics in this category directly, since new members reliably ask for…